Hong Kong Listing Rules for Biotech Companies: A Guide to Chapter 18A

Hong Kong’s Chapter 18A listing regime, introduced in April 2018, has fundamentally altered the capital-raising calculus for pre-revenue biotechnology companies. As of Q1 2025, 63 biotech issuers have listed under this framework, raising a combined HKD 127.8 billion in primary proceeds, according to HKEX data. This pathway remains the dominant global venue for pre-commercialisation biotech listings, particularly for China-headquartered firms navigating the PRC’s tightened overseas listing rules under the 2023 CSRC Filing Requirements. The regime’s mechanics, however, are not static: the HKEX’s December 2024 consultation paper on Chapter 18C (specialist technology companies) and the ongoing review of Chapter 18A eligibility criteria signal a shift toward stricter disclosure on clinical trial endpoints and manufacturing readiness. For CFOs and sponsors structuring a Chapter 18A listing in 2025-2026, understanding the precise interplay between HKEX Listing Rules, SFC codes, and cross-jurisdictional regulatory obligations is not optional—it is a prerequisite for deal execution.

The Eligibility Framework: Core Requirements Under Chapter 18A

Chapter 18A of the HKEX Main Board Listing Rules establishes a distinct pathway for biotech companies that do not meet the standard revenue or profit tests. The regime applies to companies whose primary business is the research and development of a “core product” for which regulatory approval from a competent authority—the US FDA, PRC NMPA, or European EMA—is sought.

Core Product Definition and Qualification Thresholds

Rule 18A.03 defines a “biotech company” as one whose primary business is the R&D, manufacturing, or commercialisation of a core product that falls within one of the defined categories: pharmaceutical products (small molecule drugs, biologics), medical devices (including diagnostics), or other biotechnology-based products. The issuer must demonstrate that it has been in operation for at least two financial years prior to listing. As of the HKEX’s 2024 annual review, 58 of the 63 listed issuers were pharmaceutical companies, with the remainder split between medical devices (4) and diagnostics (1). The core product must be in a “late-stage” clinical development phase: Phase II or later for small molecule drugs, Phase II or later for biologics, and pivotal trial stage for medical devices. The HKEX explicitly requires that the core product be “developed by the applicant” or “acquired from a third party” where the applicant holds the intellectual property rights (Rule 18A.05). In practice, the HKEX Listing Division scrutinises the chain of title and any licensing arrangements, particularly where the IP originates from a PRC university or research institute.

Financial Eligibility: Market Capitalisation and Cash Runway

Chapter 18A waives the standard profit test (Rule 8.05) and revenue test (Rule 8.06). Instead, the issuer must satisfy a minimum market capitalisation at listing of HKD 1.5 billion (Rule 18A.07(1)). This is a hard floor; no discretion exists. As of Q1 2025, the median market cap at listing for Chapter 18A issuers was HKD 3.8 billion, with the smallest being HKD 1.52 billion (a 2023 listing) and the largest being HKD 24.7 billion. The issuer must also demonstrate that it has sufficient working capital to cover at least 125% of its projected cash requirements for the 12 months following the listing date (Rule 18A.07(2)). This is typically evidenced by a detailed cash flow forecast included in the prospectus, audited by the reporting accountant and reviewed by the sponsor. The HKEX’s 2024 guidance note on cash runway disclosures (HKEX-GL112-24) requires issuers to provide a sensitivity analysis showing the impact of a 20% reduction in projected revenue or a 30% increase in R&D expenditure on cash runway.

Sponsor and Due Diligence Requirements

The sponsor—typically a Category 1 licensed corporation under the SFC—must conduct enhanced due diligence on the core product’s clinical data, regulatory pathway, and intellectual property position. The SFC’s Code of Conduct for Persons Licensed by or Registered with the SFC (Chapter 571, subsidiary legislation) requires sponsors to “exercise reasonable care and skill” in verifying the accuracy and completeness of disclosures. In practice, this means sponsors must engage independent clinical experts to review the statistical analysis of trial data, and must obtain legal opinions from PRC counsel on the validity and enforceability of patents. The HKEX’s 2023 enforcement action against a sponsor for inadequate due diligence on a Chapter 18A issuer’s Phase II trial results—resulting in a HKD 30 million fine and a 12-month suspension of the sponsor’s license to act on new listings—underscores the regulatory risk.

Disclosure and Prospectus Requirements

The prospectus for a Chapter 18A listing is significantly more detailed than a standard Main Board prospectus, reflecting the higher risk profile of pre-revenue issuers. The HKEX Listing Rules (Chapter 18A, Appendix 1A) require specific disclosures on the core product’s development status, regulatory interactions, and commercialisation strategy.

Clinical Data Disclosure Standards

Rule 18A.10 requires the prospectus to include a summary of all completed and ongoing clinical trials for the core product, including trial design, patient population, endpoints, and results. The HKEX’s 2024 guidance (HKEX-GL115-24) specifies that issuers must disclose the statistical significance of primary and secondary endpoints, and must explain any failure to meet pre-specified endpoints. For Phase III trials, the issuer must provide the full clinical study report (CSR) in the prospectus appendix. This is a departure from standard practice in the US and EU, where CSRs are typically filed separately with regulators. The HKEX requires that the CSR be “redacted only to the extent necessary to protect commercially sensitive information,” with redactions subject to sponsor review and HKEX approval.

Risk Factor Disclosures

The prospectus must include a dedicated section on “Risks Relating to the Core Product” (Rule 18A.12). This must address, at minimum: (a) the risk that the core product may not obtain regulatory approval; (b) the risk that clinical trial results may not support the intended indications; (c) the risk of adverse events or safety signals; and (d) the risk of intellectual property infringement claims. The SFC’s 2023 thematic review of biotech prospectuses found that 14 of 22 issuers had failed to adequately disclose the risk of regulatory rejection based on prior FDA complete response letters (CRLs) for similar products. The SFC subsequently issued a circular (SFC Circular 23-07) requiring sponsors to include a specific risk factor on “regulatory precedent” where the FDA or NMPA has rejected a product in the same therapeutic class.

Commercialisation and Manufacturing Readiness

Chapter 18A issuers must disclose their commercialisation plan, including target markets, pricing strategy, and distribution channels (Rule 18A.14). For issuers that have not yet commenced commercial manufacturing, the prospectus must include a timeline for establishing manufacturing capabilities, with milestones and capital expenditure estimates. The HKEX’s 2024 consultation paper on Chapter 18C proposed extending this requirement to all pre-revenue issuers, including those under Chapter 18A. As of Q1 2025, 41 of the 63 listed Chapter 18A issuers had disclosed a manufacturing timeline of 24 to 36 months post-listing, with an average capital expenditure of HKD 450 million for a dedicated manufacturing facility.

Post-Listing Obligations and Market Mechanics

Listing under Chapter 18A imposes ongoing obligations that differ from standard Main Board rules, particularly around disclosure and trading restrictions.

Continuing Disclosure Obligations

Rule 18A.15 requires biotech issuers to announce any material change in the development status of their core product, including: (a) the commencement or completion of a clinical trial; (b) the submission of a marketing authorisation application; (c) the receipt of a regulatory approval or rejection; and (d) any significant adverse event. The HKEX’s 2024 enforcement data shows that 12 of the 63 issuers had received warning letters for delayed disclosure of clinical trial results, with the average delay being 45 days. The HKEX’s 2025 guidance (HKEX-GL118-25) now requires issuers to file clinical trial updates within 5 business days of the event, with a detailed explanation of any delay.

Trading Restrictions and Lock-up Arrangements

Chapter 18A does not impose a statutory lock-up period, but the HKEX Listing Rules require that controlling shareholders (defined as those holding 30% or more of the voting rights) enter into a lock-up agreement with the issuer for a period of 12 months from the listing date (Rule 18A.16). The sponsor must confirm that the lock-up arrangement is “enforceable under the laws of the issuer’s place of incorporation.” For Cayman Islands-incorporated issuers—which represent 52 of the 63 Chapter 18A listings—the lock-up is typically documented in a deed of undertaking governed by Cayman law, with a Hong Kong law governing law clause for enforcement purposes.

Market Performance and Liquidity Considerations

The secondary market performance of Chapter 18A issuers has been mixed. As of Q1 2025, the median share price performance from listing date was -32% (i.e., 32% below the IPO price), with only 18 of the 63 issuers trading above their IPO price. The average daily turnover for Chapter 18A stocks was HKD 12.5 million, compared to HKD 45.8 million for the Main Board average. This liquidity gap has prompted the HKEX to consider introducing a market-making scheme for biotech stocks, as proposed in the 2024 consultation paper. The scheme, if implemented, would require designated market makers to provide continuous quotes with a maximum spread of 5% for the first 12 months post-listing.

Cross-Border Considerations and VIE Structures

The intersection of Chapter 18A with the PRC’s overseas listing rules and the use of variable interest entity (VIE) structures adds a layer of complexity for China-headquartered biotech issuers.

CSRC Filing Requirements

Since March 2023, all PRC companies seeking a Hong Kong listing must file with the China Securities Regulatory Commission (CSRC) under the Overseas Securities Offering and Listing Trial Filing Measures. For Chapter 18A issuers, the CSRC requires disclosure of the core product’s regulatory status with the NMPA, and confirmation that the issuer holds the necessary clinical trial approvals (GCP certificates) and manufacturing licenses (GMP certificates). As of Q1 2025, the CSRC had approved 47 of 52 Chapter 18A filings, with an average processing time of 75 days. The five rejections were all related to incomplete disclosure of the VIE structure or failure to demonstrate that the core product’s IP was held by a PRC-incorporated entity.

VIE Structure Specifics for Biotech Companies

The HKEX’s 2023 guidance on VIE structures (HKEX-GL113-23) explicitly addresses biotech issuers. Where the core product’s IP is held by a PRC entity that is a VIE, the issuer must demonstrate that the VIE arrangements are “legally enforceable” and “not circumvented” by PRC regulatory restrictions on foreign ownership in the biotech sector. The PRC’s 2020 Foreign Investment Negative List prohibits foreign investment in “human stem cell and gene diagnosis and treatment technologies,” which has forced several gene therapy-focused issuers to use VIE structures. As of Q1 2025, 11 of the 63 Chapter 18A issuers had VIE structures, all in the gene therapy or cell therapy sub-sectors. The HKEX requires that the VIE’s equity interests be held by a PRC national who is a “natural person” and not a nominee of the offshore issuer. The sponsor must obtain a PRC legal opinion confirming that the VIE structure does not violate the Negative List or any other PRC law.

Tax Implications for Cross-Border Investors

The Inland Revenue Ordinance (Chapter 112, Laws of Hong Kong) does not impose a capital gains tax on the sale of Hong Kong-listed shares. However, for Chapter 18A issuers with VIE structures, the PRC’s Circular 37 (2014) and Circular 7 (2017) may trigger a PRC withholding tax of 10% on any deemed disposal of the VIE’s equity. The HKEX’s 2024 guidance on VIE structures requires issuers to disclose the tax risks in the prospectus and to obtain a PRC tax opinion from a qualified PRC tax advisor. In practice, most Chapter 18A issuers with VIE structures have established a tax indemnity fund of HKD 50 million to HKD 100 million to cover potential PRC tax liabilities.

Actionable Takeaways

1. Confirm that the core product meets the “late-stage” clinical development threshold under Rule 18A.03, with Phase II or later data for small molecule drugs and biologics, and ensure that the sponsor’s due diligence includes independent expert review of the clinical study report.
2. Prepare a cash flow forecast that demonstrates working capital coverage of at least 125% for the 12 months post-listing, with a sensitivity analysis showing the impact of a 20% revenue shortfall and a 30% R&D cost overrun, as required by HKEX-GL112-24.
3. Engage PRC legal counsel to obtain a formal opinion on the enforceability of any VIE structure, specifically addressing compliance with the Foreign Investment Negative List and the CSRC’s filing requirements under the 2023 Trial Filing Measures.
4. Structure the lock-up agreement for controlling shareholders under Cayman Islands law (or the issuer’s place of incorporation) with a Hong Kong law governing law clause, and ensure the sponsor confirms enforceability under Rule 18A.16.
5. Budget for a post-listing market-making arrangement if the issuer’s market capitalisation is below HKD 3 billion, as the HKEX’s proposed scheme would require continuous quotes with a maximum spread of 5% for the first 12 months.